PAR2024-10-012024-12-31 PAR2024-10-012024-12-31 PAR2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member PAR2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member PAR2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 000000 PAR NOTLISTED Par Drugs And Chemicals Limited Equity 2024-04-01 2025-03-31 2025-02-14 2025-02-05 INR Lakhs Third quarter 15:30:00 17:12:00 2025-02-14 2025-02-14 Not applicable Single segment The Company is primarily engaged in manufacturing of API, which constitutensingle business segment in terms of Ind AS - 108 on “Operating Segments”.nAccordingly, there are no separate reportable segments as per Ind AS - 108. 2024-10-01 2024-12-31 Unaudited Standalone 213811000.00 2718000.00 216529000.00 88862000.00 0.00 -777000.00 13208000.00 141000.00 9144000.00 98227000.00 208806000.00 7724000.00 0.00 7724000.00 1944000.00 0.00 1944000.00 0.00 5780000.00 0.00 0.00 0.00 0.00 5780000.00 0.00 5780000.00 0.00 0.00 123046000.00 10 0.47 0.47 0.00 0.00 0.47 0.47 NOTES: 1. The standalone financial results of the Company have been prepared in accordance with the Ind AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, other accounting principles generally accepted in India and in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, including relevant circulars issued by the SEBI from time to time. 2. The above quarterly and nine month ended financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14th February, 2025. 3. The Statutory auditors of the company have carried out Limited Review of the above quarterly & nine month ended financial results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. 4. The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earning per share (not annualized) in accordance with the Ind AS. 5. Previous Year/Period figures are regrouped / reclassified / rearranged, whenever found necessary to make them comparable with the current period figures. 6. The Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Ind AS - 108 on “Operating Segments”. Accordingly, there are no separate reportable segments as per Ind AS - 108. 7. The Company does not have any subsidiary, associates or joint venture as on 31st December, 2024; therefore, it has prepared only standalone results as consolidation requirement is not applicable to the Company. 8. The above unaudited financial results of the Company are available on the Company’s website – www.pardrugs.com and on the website of the National Stock Exchange of India Limited (www.nseindia.com), where the Company’s shares are listed. 9. The Status of investors complaints are as follows: I. Pending at the beginning of the quarter - 0 II. Received during the quarter - 0 III. Disposed-off during the quarter - 0 IV. Remaining unresolved at the end of the quarter - 0 Single segment 2024-04-01 2024-12-31 Unaudited Standalone 786436000.00 13614000.00 800049000.00 289739000.00 0.00 -6209000.00 39418000.00 634000.00 27263000.00 292763000.00 643607000.00 156442000.00 0.00 156442000.00 39373000.00 0.00 39373000.00 0.00 117069000.00 0.00 0.00 0.00 0.00 117069000.00 0.00 117069000.00 0.00 0.00 123046000.00 10 9.51 9.51 0.00 0.00 9.51 9.51 Other expenses 98227000.00 Other expenses 292763000.00